Patents by Inventor Diane Hollenbaugh

Diane Hollenbaugh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210024642
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: January 28, 2021
    Inventors: Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming YE
  • Patent number: 10844131
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10597460
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Publication number: 20200040090
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 6, 2020
    Inventors: Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming YE
  • Publication number: 20200010558
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: September 3, 2019
    Publication date: January 9, 2020
    Inventors: Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming YE
  • Patent number: 10519243
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10400041
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 3, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Publication number: 20190071509
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: July 16, 2018
    Publication date: March 7, 2019
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10023645
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: July 17, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Publication number: 20180186889
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: February 21, 2018
    Publication date: July 5, 2018
    Inventors: Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming YE
  • Publication number: 20170349643
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 7, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20170342159
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Inventors: Diane Sau Mun COHEN, Diane HOLLENBAUGH, Shiming Ye
  • Publication number: 20160096876
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 7, 2016
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Patent number: 9192683
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 24, 2015
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Patent number: 9173957
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20140161798
    Abstract: The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.
    Type: Application
    Filed: December 2, 2013
    Publication date: June 12, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph A. Hedrick, Frederick James Monsma, Tatyana Churakova, Diane Hollenbaugh
  • Publication number: 20140140995
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 22, 2014
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20130324701
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. WILLIAMS, Elizabeth BOSCH, Stephen K. DOBERSTEIN, Kevin HESTIR, Diane HOLLENBAUGH, Ernestine LEE, Minmin QIN QIN, Ali SADRA, Justin WONG, Ge WU, Hongbing ZHANG ZHANG
  • Patent number: 8598320
    Abstract: The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph A. Hedrick, Frederick James Monsma, Jr., Tatyana Churakova, Diane Hollenbaugh
  • Patent number: 8580936
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: November 12, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang